2 results match your criteria: "Center of Biomedical Research and Innovation[Affiliation]"
Association of Bipolar Disorder With Major Adverse Cardiovascular Events: A Population-Based Historical Cohort Study.
Psychosom Med
January 2022
From the Department of Psychiatry and Psychology (Foroughi, Suarez, Prieto, Frye, Morgan), Mayo Clinic, Rochester, Minnesota; Department of Psychiatry and Behavioral Sciences (Foroughi), SUNY Downstate Health Sciences University, Brooklyn, New York; Division of Preventive Cardiology, Department of Cardiovascular Medicine (Medina Inojosa, Lopez-Jimenez, Saeidifard), Mayo Clinic, Rochester, Minnesota; Department of Medicine (Saeidifard), Northwell Health-Lenox Hill Hospital, New York, New York; International Clinical Research Center (Stokin), St. Anne's University Hospital, Brno, Czech Republic; Department of Psychiatry, Faculty of Medicine (Prieto), Universidad de los Andes; Mental Health Service (Prieto), Clínica Universidad de los Andes, Santiago, Chile; Division of Epidemiology, Department of Health Sciences Research and Department of Neurology (Rocca), Mayo Clinic, Rochester, Minnesota; and Center of Biomedical Research and Innovation (Prieto), Universidad de los Andes, Santiago. Chile.
Objective: This study aimed to assess the association of bipolar disorder (BD) with risk of major adverse cardiac events (MACEs) after adjusting for established cardiovascular disease (CVD) risk factors.
Methods: We conducted a population-based historical cohort study using the Rochester Epidemiology Project. Patients older than 30 years with a clinical encounter from 1998 to 2000 with no prior MACE, atrial fibrillation, or heart failure were followed up through March 1, 2016.
Simple method for large-scale production of macrophage activating factor GcMAF.
Sci Rep
November 2020
Laboratory of Molecular Life Science, Center of Biomedical Research and Innovation, Foundation for Biomedical Research and Innovation at Kobe, 2-2 Minatojima-Minamimachi Chuo-ku, Kobe, 650-0047, Japan.
Human group-specific component protein (Gc protein) is a multifunctional serum protein which has three common allelic variants, Gc1F, Gc1S and Gc2 in humans. Gc1 contains an O-linked trisaccharide [sialic acid-galactose-N-acetylgalactosamine (GalNAc)] on the threonine (Thr) residue and can be converted to a potent macrophage activating factor (GcMAF) by selective removal of sialic acid and galactose, leaving GalNAc at Thr. In contrast, Gc2 is not glycosylated.
View Article and Find Full Text PDF